New Muscle-Targeted IV Treatment for SMA Ages 2 and Up

Isembyld (apitegromab-mstn; Patient Information pronunciation eye-SEM-bild) is a recombinant monoclonal antibody that targets proforms of myostatin, given as an intravenous infusion. On the US Prescribing Information (revised 9/2026) it is indicated for the treatment of spinal muscular atrophy (SMA) in adults and pediatric patients 2 years of age and older who are currently receiving a survival motor neuron 2 (SMN2)-targeted treatment.

This is a traditional FDA biologic approval. On FDA’s Novel Drug Approvals for 2026 table it is row #39, approved 11 September 2026. FDA news materials describe Fast Track, Orphan Drug, and Rare Pediatric Disease designations. Scholar Rock’s USPI lists U.S. License No. 2372. Package Insert Reference ID 5868054.

Distinct path — not this carton (fact-only): Spinraza (nusinersen) and Evrysdi (risdiplam) are SMN2-targeted therapies — Isembyld is labelled only for people already on an SMN2-targeted treatment, not as a substitute for them. Zolgensma / other SMN1 gene therapies are a separate path. Today’s US labelled once-every-4-weeks muscle-targeted add-on for SMA ages 2+ on SMN2 therapy is Scholar Rock Isembyld.

Manufactured by Scholar Rock, Inc., 301 Binney Street, Cambridge, MA 02142 USA.

Where this is taking place

Commercial labelled door today: United States — FDA-labelled Isembyld for SMA ages 2+ who are currently receiving an SMN2-targeted treatment, prescribed through a neuromuscular / SMA clinic, with weight-based IV infusion every 4 weeks after dilution. Company patient materials describe Scholar Rock Supports™ for insurance, infusion logistics, and cost-support navigation and point to www.ISEMBYLD.com. This is a specialty infusion conversation — not a cure, not a replacement for SMN therapy, and not a DIY import.

Outside the United States: As of this draft, no confirmed Health Canada Notice of Compliance, European Commission marketing authorisation, MHRA licence, TGA listing, Swissmedic authorisation, or PMDA/MHLW licence for Isembyld. Do not import on your own.

SAPPHIRE / Study 1 — NCT05156320 — Randomized, double-blind, placebo-controlled, multicenter Phase 3 trial of Isembyld vs placebo in people with 5q SMA ages 2–21 who were already on nusinersen or risdiplam; all nonambulatory at baseline. Lead sponsor framing on USPI: Scholar Rock clinical program. Enrolment 188. Main efficacy population ages 2–12 (n=156 randomized framing; 53 received recommended 10 mg/kg and 50 placebo among those described for the primary analysis). Status context for access: pivotal evidence is complete for labelling — that is not the same sentence as open new enrolment into the pivotal cohort.

Honesty: Year-1 HFMSE results support the label — that is not open new enrolment into SAPPHIRE, and it is not “any infusion chair will have Isembyld tomorrow without an SMA clinician and payer review.”

The practical commercial door in the US is an SMA / neuromuscular clinician who can confirm the diagnosis and current SMN2-targeted therapy, weigh fracture risk (especially with low bone density or prior fractures), plan every-4-weeks infusion logistics, and arrange Scholar Rock Supports / payer steps if needed.

Approval matrix

Access by country

• United States: Ask a neuromuscular / SMA clinician about FDA-labelled Isembyld. Labelled 11 September 2026 for SMA in adults and children 2 years and older who are currently receiving an SMN2-targeted treatment. Path: confirm eligibility and background SMN2 therapy → weight-based 10 mg/kg diluted to 5 mg/mL in 0.9% Sodium Chloride → IV infusion over about 60–120 minutes (rate no greater than 150 mL/hour) once every 4 weeks → dedicated line with 0.2/0.22 micron PES filter; DEHP-free sets. If a dose is missed: give as soon as possible and restart the 4-week clock from that dose, or skip and resume on the original schedule. Carton: one 150 mg/3 mL (50 mg/mL) single-dose vial — NDC 84717-150-01. Store refrigerated 2–8 °C in original carton; do not freeze or shake. Suspected adverse reactions: Scholar Rock 1-855-MED-SRRK (1-855-633-7775) or FDA MedWatch 1-800-FDA-1088. Patient information: 1-877-ISEMBYLD (1-877-473-6295) or www.ISEMBYLD.com. Cost / infusion navigation: Scholar Rock Supports™ — 1-833-777-5444 (Mon–Fri 8 AM–8 PM ET on company materials) or scholarrocksupports.com (enrollment form with HCP signature). No list price or copay dollars in this article. This is US labelled commercial supply, not a DIY import.

• Canada: Isembyld authorisation not confirmed. Ask the Canadian SMA clinic what legal paths exist in Canada when a Canadian Isembyld label does not yet exist.

• European Union / United Kingdom / Australia / Japan / other countries: Regulator authorisation not confirmed in this draft. US trial sites are not a commercial foreign carton. Do not import on your own.

• If your regulator has not authorised it: do not import on your own. Ask the local clinician about documented special-access / named-patient rules, referral to a centre in a labelled country, or waiting — without treating a US vial as a foreign carton.

Who is eligible (from the US label)

This is an add-on for people already on SMN2-targeted treatment on the Prescribing Information — not a labelled stand-alone replacement for Spinraza, Evrysdi, or gene therapy, and not established under age 2.

United States (USPI, revised September 2026):

• Indication: Treatment of SMA in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment.
• Recommended dosage: 10 mg/kg IV once every 4 weeks; dilute before use; infusion ~60–120 minutes, rate ≤150 mL/hour.
• Not recommended: 20 mg/kg every 4 weeks (studied; no additional efficacy).
• Contraindications: None (USPI §4).
• Warnings: Fractures — including serious femur fractures; use caution with history of low bone density or multiple fractures; weigh risks/benefits if a fracture occurs.
• Most common adverse reactions (≥20% and more than placebo at 10 mg/kg): upper respiratory tract infections (66% vs 54%), vomiting (30% vs 16%), cough (28% vs 22%), other viral infections (26% vs 16%), headache (23% vs 16%), gastroenteritis (23% vs 8%), pharyngitis (21% vs 14%), hypersensitivity (21% vs 16%). Fractures 9% vs 2%.
• Pediatrics: Established 2 years and older; not established under 2 years.
• Pregnancy / lactation: Based on animal data, may cause fetal harm / affect reproductive function — discuss with clinician; no adequate human pregnancy data.
• Geriatrics: Studies did not include patients 65+.

SAPPHIRE trial context (USPI): All patients were on nusinersen or risdiplam and were nonambulatory at baseline. Primary efficacy ages 2–12; ages 13–21 showed a trend consistent with younger patients at the recommended dose.

Not labelled on sources confirmed for this draft:

• Use without concurrent SMN2-targeted treatment.
• Children younger than 2 years (OPAL and related studies are separate investigational paths — not this carton).
• EU, UK, Canadian, Japanese, Australian, or Swiss Isembyld marketing authorisations (not confirmed here).
• Treating completed SAPPHIRE enrolment as open commercial trial recruitment.

What the pivotal study showed (USPI)

Use the USPI for a prescription conversation. Journals are supportive reading.

Study 1 / SAPPHIRE — NCT05156320:

• Randomized 1:1:1 to Isembyld 20 mg/kg, Isembyld 10 mg/kg, or placebo IV every 4 weeks for about 1 year.
• 188 patients with 5q SMA, ages 2–21, all on SMN2-targeted therapy, all nonambulatory at baseline.
• Primary endpoint (ages 2–12): change from baseline in HFMSE at 1 year.

USPI Table 2 framing (ages 2–12, recommended 10 mg/kg):

How to talk with a doctor

Bring this page and ask a neuromuscular / SMA clinician:

1. “I / my child is already on nusinersen or risdiplam (or another labelled SMN2 therapy). Does labelled US Isembyld fit as an add-on?”
2. “What is our fracture history and bone-density risk, and how would you monitor that?”
3. “Where would the every-4-weeks IV be given, and who handles prior authorisation?”
4. “Can we enroll in Scholar Rock Supports for insurance and infusion logistics?”
5. If outside the US: “Has our regulator authorised Isembyld, or what legal special-access options exist?”

Who is involved (from primary sources)

• Sponsor / manufacturer: Scholar Rock, Inc., Cambridge, MA (U.S. License No. 2372).
• Pivotal trial: SAPPHIRE / Study 1 (NCT05156320) — multicenter Phase 3 program supporting the US label.
• Patient support (company): Scholar Rock Supports™ — 1-833-777-5444; medical AE line 1-855-633-7775; product info 1-877-473-6295.

Names and roles above are limited to what appears on the primary sources cited. Contacts not listed on those sources are omitted.

Primary sources

1. Scholar Rock US Prescribing Information for ISEMBYLD (apitegromab-mstn) — Revised 9/2026; Reference ID 5868054 — https://scholarrock.com/documents/label/us/ISEMBYLD_PI.pdf
2. FDA Novel Drug Approvals for 2026 — row #39 Isembyld, 9/11/2026 — https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
3. FDA news: FDA Approves First Therapy to Target Muscle Loss in Spinal Muscular Atrophy — content current as of 09/11/2026 — https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-therapy-target-muscle-loss-spinal-muscular-atrophy
4. ClinicalTrials.gov — SAPPHIRE NCT05156320
5. Scholar Rock Supports patient site — https://www.scholarrocksupports.com/

Not medical advice. Talk with a clinician who knows the full history before any treatment decision. Authorized is not funded.